Neurodegenerative disease: Pridopidine for Huntington disease falls short of primary efficacy end point in phase III trial

  • Published 2011 in Nature Reviews Neurology

Abstract

Sorry, we couldn't extract an abstract for this paper.
DOI: 10.1038/nrneurol.2011.208

Topics

  • Presentations referencing similar topics